Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Novartis wagers almost $8B on a Chinese biotech's RNA drugs

2 October 2026 · By · Wire by Fusion42

Published

2 October 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 3 October 2026 · Fusion42 review

Novartis has made a nearly $8 billion investment deal with Chinese biotech Abogen Biosciences, beginning with a $575 million upfront payment for access to its RNA technology and an option to license its lead program ABO-2203.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Global biotech founders should note the rising validation of RNA tech from Chinese innovation hubs, signalling stronger cross-border investment flows and partnership opportunities in RNA therapeutics.

◆ Coverage

1 source · 2 Oct 2026

◆ Related on Wire

◆ Topics

Biotechbiotechrna-therapeuticschinapharma-investmentnovartis